Keyphrases
Tuberous Sclerosis Complex
100%
Transcriptional Profiling
50%
Major Depressive Disorder
50%
Gray Matter Volume
50%
MicroRNA-34a (miR-34a)
50%
Early Brain Development
50%
Corticogenesis
50%
Cell Adhesion Molecules
50%
Early Postnatal Period
50%
Multiple Sclerosis Lesions
50%
Sex-specific
50%
Sex Differences
50%
Microglia
50%
White Matter
43%
Steroid Levels
33%
Neuroactive Steroids
33%
Multiple Sclerosis
33%
Disease Progression
33%
Progesterone
33%
Cortical Tuber
32%
Gene Expression
31%
Gray Matter
25%
Microglial Cells
21%
Astrocytes
20%
Mammalian Target of Rapamycin (mTOR)
19%
Dehydroepiandrosterone
16%
No Significant Difference
16%
Testosterone
16%
Female-specific
16%
Gas Chromatography-mass Spectrometry
16%
Human Fetus
16%
Disease Susceptibility
16%
Metabolic Enzymes
16%
Beneficial Effects
16%
Estradiol
16%
Glutamate Transporter 1 (GLT-1)
16%
Neuroinflammatory Response
16%
Multiple Sclerosis Treatment
16%
Insulin-like Growth factor-1
16%
Androgens
16%
Inflammatory Conditions
16%
Steroidogenic Enzyme Expression
16%
Steroid Receptors
16%
Cytokine Expression
16%
Tuber
15%
Control Tissue
13%
Overexpression
11%
Low Expression
10%
Quantitative PCR
10%
Complex Patients
10%
Neuroscience
Tuberous Sclerosis
100%
Microglia
58%
Brain Development
55%
Major Depressive Disorder
50%
microRNA 34a
50%
Corticogenesis
50%
Gray Matter
50%
Cell Adhesion Proteins
50%
Multiple Sclerosis
50%
Gene Expression
32%
Mammalian Target of Rapamycin Complex 1
25%
Astrocyte
18%
In Vitro
18%
Protein Expression
18%
Receptor
16%
Progesterone
16%
Western Blot
14%
Immunohistochemistry
14%
Transfection
10%
Neuroblastoma
10%
Comorbidity
10%
Real-Time Polymerase Chain Reaction
9%
Staining Technique
9%
Gas Chromatography
8%
Androgen
8%
Neuroprotective Agent
8%
Neuroactive Steroid
8%
Allopregnanolone
8%
Diethylstilbestrol
8%
Brain-Derived Neurotrophic Factor
8%
Mass Spectrometry
8%
Dehydroepiandrosterone
8%
Insulin-Like Growth Factor 1
8%
Cytokine
8%
Cell Line
5%
Cell Adhesion
5%
Epileptic Seizure
5%
Brain Abnormalities
5%
Pervasive Developmental Disorder
5%
In Situ Hybridization
5%
Transcriptomics
5%
